Close

RBC Capital Defending Sarepta Therapeutics (SRPT), 'we believe weakness presents a buying opportunity' May 24, 2023 08:48AM
RBC Capital Defending Sarepta Therapeutics (SRPT), 'we see value in SRPT's gene therapy programs that is not captured at current levels and remain buyers', PT $150 Apr 21, 2022 10:33AM
Sarepta Therapeutics (SRPT) Prices 6.17M Share Offering at $81/sh Oct 14, 2021 05:44AM
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock Oct 13, 2021 09:15PM
Sarepta Therapeutics (SRPT) PT Raised to $133 as RBC Capital Sees a Slim Possibility of an Early Filing Mar 12, 2021 06:08AM
View Older Stories

Sep 18, 2020 06:25AM 3 Reasons RBC Capital Thinks the Sarepta Therapeutics (SRPT) Patent Infringement Suit is not Meaningful
Jun 18, 2020 09:26AM Pre-Open Stock Movers 06/18: (ALPN) (AEMD) (ELOX) Higher; (LPTX) (QUIK) (BIIB) Lower (more...)
May 12, 2020 04:30PM Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference
Feb 27, 2020 06:21AM Sarepta Therapeutics (SRPT) PT Raised to $213 at RBC Capital
Feb 25, 2020 11:03AM Sarepta Therapeutics (SRPT) May Have Sold Priority Review Voucher to Vifor - RBC
Jan 22, 2020 09:36AM RBC Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT) on Release of Full CRL Letter
Dec 23, 2019 08:05AM Sarepta Therapeutics (SRPT) PT Lowered to $200 at RBC Capital
Dec 13, 2019 06:19AM Sarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'
Oct 10, 2019 07:12AM Sarepta Therapeutics (SRPT) Defended at RBC
Sep 24, 2019 07:32AM Sarepta Therapeutics (SRPT) Presenting Functional LGMD2E Data on 10/5 - RBC Capital
Aug 20, 2019 06:43AM Sarepta Therapeutics (SRPT) PT Lowered to $204 at RBC Capital
Aug 8, 2019 07:50PM Sarepta says adverse event report for DMD gene therapy erroneously submitted
Aug 8, 2019 01:08PM FDA Adverse Event May Not Be 'Major Showstopper' for Sarepta Therapeutics (SRPT) Program - RBC
Aug 8, 2019 07:04AM Sarepta Therapeutics (SRPT) PT Lowered to $218 at RBC Capital
Jul 1, 2019 06:18AM Sarepta Therapeutics (SRPT) PT Raised to $220 at RBC Capital; Emrges as Clear Leader in DMD
May 14, 2019 08:59AM Sarepta (SRPT) Has $3B +Additional Opportunity Beyond DMD/LGMD - RBC
May 9, 2019 06:49AM Sarepta Therapeutics (SRPT) PT Lowered to $188 at RBC Capital
Feb 28, 2019 06:51AM Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company
Jan 17, 2019 06:41AM RBC Capital Weighs in Sarepta Therapeutics (SRPT) Confusion/Skepticism; Trims PT to $164
Jan 7, 2019 03:06PM UPDATE: Sarepta Therapeutics (SRPT) Defended at RBC Capital
Jan 3, 2019 03:59PM Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
Oct 25, 2018 07:30AM Sarepta Therapeutics (SRPT) PT Lowered to $190 at RBC Capital
Oct 4, 2018 09:58AM KOL Agrees that Sarepta (SRPT) High Microdystrophin Expression is Not Worrisome - RBC
Sep 26, 2018 07:29AM Sarepta Therapeutics (SRPT) PT Raised to $200 at RBC Capital Following Management Meetings
Aug 9, 2018 08:48AM Sarepta Therapeutics (SRPT) PT Lowered to $187 at RBC Capital
Jun 20, 2018 07:13AM Sarepta Therapeutics (SRPT) PT Raised to $189 at RBC Capital
Jun 18, 2018 10:19AM RBC Positive on Sarepta Therapeutics (SRPT) Into Tomorrow's R&D Day
May 31, 2018 03:56PM RBC Positive on Biogen (BIIB) Karp Hire Amid Partnerships/M&A Potential
May 18, 2018 10:33AM Sarepta Therapeutics (SRPT) PT Raised to $112 at RBC Capital
May 4, 2018 08:50AM Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC Capital
Apr 3, 2018 06:07AM RBC Likes Set-Up for Sarepta Therapeutics (SRPT) Shares
Mar 12, 2018 09:40AM Sarepta Therapeutics (SRPT) PT Raised to $91 at RBC Capital
Jan 22, 2018 05:43AM RBC Capital Assumes Sarepta Therapeutics (SRPT) at Outperform
Oct 17, 2017 06:33AM Sarepta Therapeutics (SRPT): Neurologists Survey Shows Strong Adoption of Exondys 51 - RBC
Apr 28, 2017 07:56AM Sarepta Therapeutics (SRPT) PT Lowered to $60 at RBC Capital
Mar 1, 2017 06:35AM Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital
Dec 16, 2016 07:45AM KOLs Expect Sarepta (SRPT) EXONDYS 51 Reimbursement Issues to be Overcome, RBC Says; PT Trimmed to $98
Dec 15, 2016 10:50AM Sarepta (SRPT) Gains as RBC Survey Suggests Docs Willing to Widely Use
Dec 1, 2016 11:02AM RBC Recommends Buying Sarepta (SRPT) on Weakness Related to UnitedHealthcare Commercial Drug Policy
Nov 11, 2016 01:03AM Trump presidency could prove a salve for pharma merger deals
Oct 17, 2016 11:21AM RBC Affirms PTC Therapeutics (PTCT) at 'Sector Perform'; Doesn't See Translarna Appeal with Solid Chance
Oct 4, 2016 09:01AM Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC
Sep 28, 2016 03:05PM Notable 52-Week Highs and Lows 9/28: (SRPT) (NVDA) (CLD) High; (FGP) (GBSN) Low
Sep 28, 2016 09:10AM Pre-Open Stock Movers 09/28: (SEED) (AVXL) (ATHX) Higher; (GALT) (TPX) (SONC) Lower (more...)
Sep 28, 2016 07:25AM Sarepta Therapeutic (SRPT) PT Raised Sharply to 'Street High' $108 at RBC Capital
Sep 19, 2016 01:52PM RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target
Jul 14, 2016 09:59AM FDA Rejection of Santhera Matters for Sarepta (SRPT), and Not in a Good Way - RBC Capital
Jun 9, 2016 09:27AM Pre-Open Stock Movers 06/09: (ACUR) (CBK) (RADA) Higher; (RH) (INSM) (TMH) Lower (more...)
Jun 8, 2016 06:04PM After-Hours Stock Movers 06/08: (RADA) (MSTX) (EAT) Higher; (RH) (INSM) (TMH) Lower (more...)
Jun 2, 2016 12:57PM New Expanded Access Guidance Could Provide FDA a Way Out on Sarepta's (SRPT) Eteplirsen - RBC
View Older Stories